Skip to main content
NCBI home page
Molecules logoLink to Molecules
. 2023 Mar 14;28(6):2632. doi: 10.3390/molecules28062632

Identification of Sildenafil Compound in Selected Drugs Using X-ray Study and Thermal Analysis

Izabela Jendrzejewska 1,*, Tomasz Goryczka 2, Ewa Pietrasik 1, Joanna Klimontko 3, Josef Jampilek 4
Editor: Fengqing Yang
PMCID: PMC10051464  PMID: 36985604

Abstract

Twelve drugs containing sildenafil compounds (sildenafil citrate and sildenafil base) were examined using X-ray studies and thermal analysis. According to the manufacturer’s information, the presence of sildenafil was confirmed in all investigated drugs. The positions of diffraction lines (value of 2θ angle) agree with the patterns presented in the ICDD database, Release 2018 (ICDD—International Centre of Diffraction Data). The difference expresses the agreement in the position of the diffraction line between the tested substance and the standard. A good agreement is when this difference is less than 0.2°. The values of interplanar distances dhkl are also compatible with the ICDD database. It indicated that the drug examined was genuine. Because all drugs are mixtures of different substances (API and excipients), the various diffraction line intensities were detected in all observed X-ray images for the tested drugs. The intensity of the diffraction line depends on many factors, like the amount of substance, coexisting phases, and mass absorption coefficient of the mixture. The thermal analysis confirmed the results obtained by the X-ray study. On DSC curves, the endothermic peaks for sildenafil compounds were observed. The determined melting points of sildenafil compounds corresponded to the values available in the literature. The results gathered by connecting two methods, X-ray study and thermal analysis, can help identify irregularities that may exist in pharmaceutical specimens, e.g., distinguishing genuine from counterfeit products, the presence of a correct polymorph, a lack of active substance, an inaccurate amount of the active substance, or excipients in the tested drug.

Keywords: sildenafil, X-ray study, quality phase analysis, thermal measurements

1. Introduction

Since 1985, Pfizer chemists have been working to develop new phosphodiesterase (PDE) inhibitors that degrade cyclic guanosine-3′,5′-monophosphate (cGMP) as potential drugs for cardiovascular diseases (hypertension and angina pectoris). Sildenafil (see Figure 1), a synthetic analogue of purine compounds, was first prepared by Bell, Brown, and Terrett in 1989 and soon became a lead compound after biological and pharmacokinetic tests [1,2]. Two years later, the first clinical trials of sildenafil for the treatment of angina pectoris were initiated within the Pfizer company. This study concluded that there are several side effects; among the most common, such as headache and muscle pain, spontaneous erection in men was surprisingly recorded. Since such a strong side effect had never been observed before and insignificant effects of sildenafil in the treatment of angina pectoris had been demonstrated in phase I clinical testing, Pfizer decided to reconsider the strategy, and the first phase II clinical trials of sildenafil have already focused directly on the treatment of erectile dysfunction (ED) [1].

Figure 1.

Figure 1

Open in a new tab

Structure of sildenafil (5-{2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-1-methyl- 3-propyl-1,6-dihydro-7H-pyrazolo [4,3-d]pyrimidin-7-one), CAS 139755-83-2, ATC code G04BE03.

On a side note, it is good to remember that more than half of men over 40 suffer from some form of ED, and around 50% of them go untreated. In many cases, ED is the first symptom of common or even serious diseases such as hypertension, diabetes, cardiovascular disease, nervous system disorders (multiple sclerosis, Parkinson’s disease), and others [3,4].

Based on the results of the studies, Pfizer applied to the FDA for registration of sildenafil under the trade name Viagra® (containing sildenafil citrate) for the treatment of ED, and in 1998 this “New Drug Application” No. 20-8954 was approved [1,5,6]. After the launch of Viagra® by the pharmaceutical company Pfizer Inc. (New York, NY, USA) [6], there was a wave of publicity and interest from both scientists and potential users themselves, which was to some extent caused by the atypical shape and colour of the tablet. However, it must be acknowledged that the medicament Viagra® revolutionised the treatment of ED mainly due to a sophisticated marketing strategy.

The discovery of sildenafil and, above all, its “innovative” application for the treatment of ED meant an economic success for Pfizer, which generated enormous interest in this molecule among its competitors. In 2013, Viagra® patent protection expired in Europe and Canada, prompting the expansion of generic equivalents into the market. Currently, the worldwide sale of generic Viagra® is allowed (in the USA, Pfizer managed to defend the effectiveness of the patent and thus maintain exclusivity until April 2020) [7]. After its launch in 1998 in the USA and the countries of the European Union, it became the fastest-selling drug ever by 2012, which speaks volumes about the economic potential of this molecule [8,9]. However, the market is currently full of generic products containing sildenafil, and these products are also a grateful target for many drug counterfeiters [6,10].

The results of investigations of the original Viagra® tablets and some counterfeit imitations of Viagra were described in [11].

This work presents research results on various drugs containing sildenafil as an active pharmaceutical ingredient (API). Our work is a continuation of our previous study, which focused on examination drugs with acetaminophen and acetylsalicylic acid as well as on various dietary supplements using a combination of the following methods: X-ray Powder Diffraction method (XRPD), Differential Scanning Calorimetry (DSC), and Thermogravimetry (TG) [12,13,14,15]. The main goal of this work was to use phase analysis to identify sildenafil. Moreover, we tried to present the attempt to determine whether the product was original. Nine Over-the-Counter (OTC) drugs were chosen for this research, and three were on prescription.

2. Results and Discussion

2.1. X-ray Analysis

Our investigations focused on the qualitative analysis of drugs containing sildenafil API. Generally, drugs’ phase composition comprises API(s) and excipients. Each drug is a mixture of various components. The examined drugs include the following sildenafil APIs: sildenafil citrate and sildenafil base. The X-ray diffraction images of both these compounds are presented in Figure 2. The images were prepared using X-ray data from the X-ray diffraction database ICDD PDF4 (ICDD—International Centre of Diffraction Data, PDF—Powder Diffraction File) [16].

Figure 2.

Figure 2

Open in a new tab

X-ray diffraction images for sildenafil citrate (a) and sildenafil base (b).

For sildenafil citrate, the diffraction line with the 100% relative intensity exists at 2θ = 14.4612° (112), whereas, for sildenafil base, the diffraction line with the 100% relative intensity exists at 2θ = 5.1545° (020). The qualitative X-ray analysis makes it possible to identify crystalline phases in the investigated samples. Each polycrystalline compound possesses a typical X-ray image consisting of diffraction lines. Each diffraction line has a specific position and intensity. The diffraction lines are formed even when the size of crystallites is in the order of a dozen or so unit cells in the direction of each crystallographic axis. It is, therefore, possible to identify substances with submicroscopic grain sizes. The particular place is expressed by the value of the 2θ angle at which the diffraction phenomenon occurs. The intensity of the line defines the number of counts.

It is worth highlighting that each polycrystalline phase retains its characteristic arrangement of diffraction lines in the mixture. For this reason, the substance’s X-ray image is called “fingerprints”. This procedure compares the experimental diffraction data (2θ diffraction angles, dhkl interplanar distances) with the data from the ICDD database [17]. Values of dhkl interplanar distances were calculated based on the Bragg–Wulff equation. The most important thing is to compare the 2θ angles because the shift of the line by more than 0.2° at a given diffraction angle of 2θ will indicate the presence of a different crystal structure. Such a phenomenon in an examined sample can be considered suspicious [18,19]. The absence of diffraction lines does not mean that a given phase is absent. Its amount may be below the X-ray detection limit (“sensitivity of the method”), i.e., below the lower percentage of the substance at which its diffraction pattern is not registered [12,13].

The results of the X-ray study of selected drugs with sildenafil are shown in Figure 3, Figure 4 and Figure 5 and Table 1 and Table 2. The value J/Jmax presents the relative intensity of the diffraction line, expressed as the ratio of the intensity of a given diffraction line to the intensity of the strongest diffraction line visible in the diffraction pattern.

Figure 3.

Figure 3

Open in a new tab

X-ray pattern for drugs containing sildenafil citrate: (a) Viagra®, (b) Sildena®, and Ernafil®. These drugs require a prescription.

Figure 4.

Figure 4

Open in a new tab

X-ray pattern for Over-the-Counter (OTC) drugs containing sildenafil citrate. Inset: the convolution of three diffraction lines of Mg stearate, lactose monohydrate, and sildenafil citrate.

Figure 5.

Figure 5

Open in a new tab

X-ray pattern for Over-the-Counter (OTC) drugs containing sildenafil base.

Table 1.

Comparison of experimental and diffraction data from the ICDD database for drugs containing sildenafil citrate (C28H38N6O11S) compatible with the PDF card 00–052–2420.

No. of
Diffraction Line		 2θ (o)
Exp.		 2θ (o)
ICDD		 J/Jmax (%) Exp. J/Jmax (%) ICDD |Δ2θ| * dhkl (Å)
Exp.		 dhkl (Å)
CDD		 hkl **
Viagra®
1. 7.3981 7.3730 27 16 0.0251 11.94 11.98 010
2. 8.1870 8.1122 41 89 0.0748 10.79 10.89 110
3. 10.2926 10.3135 33 42 0.0209 8.59 8.57 300
4. 14.4514 14.4612 42 100 0.0098 6.12 6.12 112
5. 19.9320 19.8997 57 39 0.0323 4.45 4.46 42-1
6. 23.0929 23.0460 93 23 0.0469 3.85 3.86 52-2
Ernafil®
1. 7.3615 7.3730 10 16 0.0115 12.00 11.98 010
2. 8.0668 8.1122 15 89 0.0454 10.95 10.89 110
3. 10.3448 10.3135 13 42 0.0313 8.54 8.57 300
4. 14.3992 14.4612 11 100 0.0620 6.15 6.12 112
5. 20.0366 19.8997 100 39 0.1369 4.43 4.46 42-1
6. 22.9624 23.0460 25 23 0.0836 3.87 3.86 52-2
Sildena®
1. 7.3824 7.3730 11 16 0.0094 11.96 11.98 010
2. 8.0564 8.1122 14 89 0.0558 10.97 10.89 110
3. 10.2508 10.3135 13 42 0.0313 8.62 8.57 300
4. 14.4671 14.4612 14 100 0.0059 6.12 6.12 112
5. 19.9739 19.8997 100 39 0.0742 4.44 4.46 42-1
6. 23.0407 23.0460 63 23 0.0053 3.86 3.86 52-2
Valinger®
1. 7.3981 7.3730 25 16 0.0251 11.94 11.98 010
2. 8.0825 8.1122 32 89 0.0297 10.93 10.89 110
3. 10.2926 10.3135 28 42 0.0209 8.59 8.57 300
4. 14.4514 14.4612 38 100 0.0098 6.12 6.12 112
5. 19.8276 19.8997 43 39 0.0721 4.48 4.46 42-1
6. 23.2341 23.0460 53 23 0.1881 3.83 3.86 52-2
ActiGra®
1. 7.3992 7.3730 20 16 0.0262 11.94 11.98 010
2. 8.2111 8.1122 29 89 0.0989 10.76 10.89 110
3. 10.3469 10.3135 27 42 0.0361 8.54 8.57 300
4. 14.4723 14.4612 32 100 0.0111 6.11 6.12 112
5. 19.9289 19.8997 45 39 0.0292 4.45 4.46 42-1
6. 23.0930 23.0460 64 23 0.0470 3.85 3.86 52-2
Silcontrol®
1. 7.3824 7.3730 23 16 0.0094 11.96 11.98 010
2. 8.0564 8.1122 31 89 0.0558 10.96 10.89 110
3. 10.3083 10.3135 25 42 0.0052 8.57 8.57 300
4. 14.4096 14.4612 33 100 0.0516 6.14 6.12 112
5. 19.8641 19.8997 42 39 0.0356 4.47 4.46 42-1
6. 23.0407 23.0460 63 23 0.0053 3.86 3.86 52-2
Maxon®
1. 7.4922 7.3730 23 16 0.1192 11.79 11.98 010
2. 8.1714 8.1122 31 89 0.0592 10.81 10.89 110
3. 10.3605 10.3135 31 42 0.0470 8.53 8.57 300
4. 14.5246 14.4612 43 100 0.0634 6.09 6.12 112
5. 19.9774 19.8997 66 39 0.0777 4.44 4.46 42-1
6. 23.0930 23.0460 96 23 0.0470 3.85 3.86 52-2
PrinceX®
1. 7.3458 7.3730 25 16 0.0270 12.02 11.98 010
2. 8.0825 8.1122 38 89 0.0297 10.93 10.89 110
3. 10.3448 10.3135 33 42 0.0313 8.54 8.57 300
4. 14.3992 14.4612 28 100 0.0620 6.15 6.12 112
5. 19.8798 19.8997 40 39 0.0199 4.46 4.46 42-1
6. 23.0930 23.0460 62 23 0.0470 3.85 3.86 52-2
Open in a new tab

* absolute value of the difference between the experimental value of 2θ and the value of 2θ from the ICDD database; ** Miller’s indices of diffraction lines.

Table 2.

Comparison of experimental and diffraction data from the ICDD database for drugs containing sildenafil base compatible with the PDF card 00–052–2006.

No. of
Diffraction Line		 2θ (o)
Exp.		 2θ (o)
ICDD		 J/Jmax (%) Exp. J/Jmax (%) ICDD |Δ2θ| * dhkl (Å)
Exp.		 dhkl (Å)
ICDD		 hkl **
DoppelSil®
1. 5.2089 5.1545 13 100 0.0544 16.95 17.13 020
2. 10.3866 10.3256 11 62 0.0610 8.51 8.56 040
3. 16.4159 16.3409 27 6 0.0750 5.40 5.42 051
4. 17.1525 17.1703 13 6 0.0178 5.17 5.16 131
5. 22.8631 22.8538 16 9 0.0093 3.89 3.88 090
6. 25.5695 25.4645 22 11 0.1050 3.48 3.49 25-1
Maxigra®
1. 5.0236 5.1545 16 100 0.1309 17.58 17.13 020
2. 10.2202 10.3256 15 62 0.1054 8.65 8.56 040
3. 16.2660 16.3409 43 6 0.0749 5.44 5.42 051
4. 16.9891 17.1703 17 6 0.1812 5.21 5.16 131
5. 22.6831 22.8538 19 9 0.1707 3.92 3.88 090
6. 25.4501 25.4645 22 11 0.0144 3.50 3.49 25-1
Mensil®
1. 5.0107 5.1545 17 100 0.1438 17.62 17.13 020
2. 10.1835 10.3256 16 62 0.1421 8.68 8.56 040
3. 16.2746 16.3409 44 6 0.0663 5.44 5.42 051
4. 16.9755 17.1703 15 6 0.1948 5.22 5.16 131
5. 22.6646 22.8538 18 9 0.1892 3.92 3.88 090
6. 25.4194 25.4645 20 11 0.0451 3.50 3.49 25-1
Inventum™
1. 5.0236 5.1545 15 100 0.1309 17.58 17.13 020
2. 10.1865 10.3256 14 62 0.1391 8.68 8.56 040
3. 16.2379 16.3409 37 6 0.1030 5.45 5.42 051
4. 16.9797 17.1703 16 6 0.1906 5.22 5.16 131
5. 22.6694 22.8538 17 9 0.1844 3.92 3.88 090
6. 25.4164 25.4645 19 11 0.0481 3.50 3.49 25-1
Open in a new tab

* absolute value of the difference between the experimental value of 2θ and the value of 2θ from the ICDD database; ** Miller’s indices of diffraction lines.

2.1.1. X-ray Study for Drugs with Sildenafil Citrate

X-ray diffraction patterns for drugs containing sildenafil citrate API are shown in Figure 3 and Figure 4.

Figure 3 and Figure 4 show that the diffraction lines derived from sildenafil citrate are visible. The diffraction lines align with the ICDD database pattern (PDF 00–052–2420). We considered six of the strongest diffraction lines visible on the diffraction pattern to compare the value of 2θ angle and calculations of interplanar distances dhkl.

Values |Δ2θ| are below 0.2°, which indicates the presence of sildenafil citrate in the examined drugs. Furthermore, the good agreement indicates that the sildenafil citrate is in proper crystallographic form (i.e., the same structural parameters). Additionally, the values of interplanar distances dhkl are consistent with the data presented in the ICDD database. We observed only the inconsistent values in the diffraction line’s intensities. The strongest line of examined drugs is placed at another 2θ angle compared to the pattern from the ICDD database (Table 1). The intensity of diffraction lines depends on their amount in the mixture, the crystal structure, the nature of the phases coexisting with it, and the mass absorption coefficient. The observed change in diffraction line intensity can indicate that in these drugs, the preferred grain orientation occurs at different values 2θ angle.

In the diffraction pattern for Sildena® and Ernafil®, the strongest diffraction lines derived from Mg stearate and lactose monohydrate were detected. The line with the highest intensity belongs to Mg stearate, probably because a preferred orientation of the grains appeared in Mg stearate, significantly affecting the line’s intensity. Viagra® also contains Mg stearate and lactose monohydrate. Still, their diffraction lines are overlapped by the diffractograms of amorphous components, which indicates that they are present in a high proportion in the composition of Viagra®.

The presence of Mg stearate and lactose monohydrate is also confirmed for the drugs presented in Figure 4. Although the convolution of three diffraction lines deriving from Mg stearate, lactose monohydrate, and sildenafil citrate is observed. This phenomenon is a result of very similar values of 2θ angle for the diffraction lines (lactose monohydrate—19.6679°, Mg stearate—19.7876°, and sildenafil citrate—19.8997°). The values of 2θ angle for Mg stearate and lactose monohydrate correspond to the positions of the strongest diffraction lines.

2.1.2. X-ray Study for Drugs with Sildenafil Base

The results of the X-ray study for drugs with a sildenafil base are shown in Figure 5.

For tested drugs containing sildenafil base, the diffraction lines’ positions agree with the sildenafil base data (PDF Card 00–052–2006, Figure 2b), which confirms the presence of this compound in these drugs. The comparison of the experimental values of 2θ angle with the values presented in the ICDD database pointed out that the absolute value of the difference between these values is less than 0.2° (Table 2). For these drugs, the diffraction lines, typical for Mg stearate and lactose monohydrate are visible (Figure 5). The line of Mg stearate is the strongest, which indicates that the preferred grain orientation is detectable in the same phenomenon mentioned earlier.

Similarly, to the data for drugs with sildenafil citrate, the calculations done for drugs with sildenafil citrate indicate that the sildenafil base given in the examined drugs is in good crystal form.

2.2. Thermal Analysis

2.2.1. Drugs with Sildenafil Citrate

Figure 6, Figure 7 and Figure 8 present the results of thermal analysis for drugs containing sildenafil citrate. Figure 6 shows the DSC (DSC—Differential Scanning Calorimetry) and TG/DTG (TG—Thermogravimetry, DTG—Derivative of Thermogravimetry) curves for drugs with sildenafil citrate that are available by prescription.

Figure 6.

Figure 6

Open in a new tab

X-ray DSC and TG/DTG curves for drugs on prescription: (a) Viagra®, (b) Sildena®, and (c) Ernafil®.

Figure 7.

Figure 7

Open in a new tab

DSC and TG/DTG for Over-the-Counter (OTC) drugs with sildenafil citrate: (a) ActiGra®, (b) Silcontrol®, and (c) Maxon®.

Figure 8.

Figure 8

Open in a new tab

DSC and TG/DTG for Over-the-Counter (OTC) drugs with sildenafil citrate: (a) PrinceX® and (b) Valinger®.

According to the literature data, the DSC curve for Viagra® shows that the first endothermic peak appears at a temperature of 189 °C [20,21]. It is worth highlighting that, based on much of the literature data, the melting point of pure sildenafil citrate is in the range 182–196 °C [22,23]. Whereas, in Ref. [24], the sharp endothermic peak indicating the melting point of sildenafil citrate is reported at 203.7 °C. The thermoanalytical DSC and TG curves of Viagra® are depicted in Figure 6. A small mass loss (about 1.5%) is observed on the TG curve, which is connected with the dehydration of sildenafil citrate. The next mass loss (about 6%) is observed in the temperature range between 185 °C and 205 °C and is connected with the citric acid evaporation [24], as well as with the process of melting of Viagra®. The endothermic peak, visible at 189 °C (Figure 6), indicates the phase transition between the solid state and liquid of Viagra®.

In the temperature range between 280 °C and 340 °C, a significant mass loss is observed (about 50%). The second endothermic peak appears at 303 °C. The place of this peak is consistent with the peak on DTG curves. At this temperature, the incineration of Viagra® takes place. The flash point’s determined value is lower than that of pure sildenafil citrate (360 °C) [25,26]. In a mixture of substances, the endothermic peaks may be shifted towards lower temperatures.

DSC curves for Sildena® and Ernafil® show the first endothermic peak at 148 °C. It indicates the melting point of Mg stearate (mp 130–150 °C [27,28]), which is given in the composition of these drugs. It should be noted that the melting point value for Mg stearate is various and depends on the source, but Merck gives the value 140 °C [29]. Many sources present a temperature of 88 °C or 200 °C as a melting temperature [30,31].

The second endothermic peak observed on the DSC curves of examined drugs is a combination of two peaks: the first part indicates the melting point of sildenafil citrate (mp 184–196 °C [22,23]) at temperatures of 188 °C and 183 °C for Sildena® and Ernafil®, respectively. The second part of the peak indicates the melting point of lactose monohydrate (mp 202–215 °C [32,33]) at temperatures of 202 °C and 199 °C for Sildena® and Ernafil®, respectively. The results of DSC/TG measurements correspond to those obtained by X-ray analysis. For both drugs, the decomposition and mass loss take place above 330 °C (Figure 6a,b). The results of DSC/TG measurements correspond to those obtained by X-ray analysis.

Figure 7 and Figure 8 show the DSC and TG/DTG curves for OTC drugs containing sildenafil citrate.

The shape of the DSC and TG/DTG curves for OTC drugs with sildenafil citrate is very similar and agrees with the Viagra DSC/TG curves and the literature data. The melting point for tested drugs has almost the same value (189–191 °C), while the decomposition temperature is higher than that of pure sildenafil citrate and Viagra®. It may be connected with the presence of different excipients in the examined drugs.

The thermal parameters such as onset, offset, peak maximum, and mass loss for drugs containing sildenafil citrate are presented in Table 3.

Table 3.

Thermal parameters obtained from DSC/TG analysis for selected drugs containing sildenafil citrate.

No. Name of Drug Weight Loss (%) Onset (°C) Offset (°C) Peak Maximum (°C) Peak Height (mW) Peak Area (J) Enthalpy (J/g)
1 Viagra® 55 185 194 189 3.75 0.52 72.6
290 303 298 2.29 0.74 103
2 Ernafil® 65 144 153 148 3.10 0.25 52.3
189 210 183, 199 3.00 0.67 140
3 Sildena® 68 144 151 148 4.48 0.54 75.1
181 214 188, 202 4.47 1.50 209
4 Valinger® 63 177 197 190 3.87 0.60 97.5
343 357 348 0.48 0.08 13.4
5 ActiGra® 55 185 196 189 3.36 0.51 93.3
345 356 354 0.43 0.07 13.4
6 Silcontrol® 65 180 195 190 4.23 0.66 107
328 334 334 0.77 0.28 44.4
7 Maxon® 72 187 196 191 3.02 0.31 66.4
343 367 353 0.73 0.25 52.7
8 PrinceX® 49 187 197 191 5.05 0.69 103.1
314 324 319 0.46 0.05 8.10
Open in a new tab

2.2.2. Drugs with Sildenafil Base

The shape of the DSC and TG/DTG curves for drugs with a sildenafil base is very similar (Figure 9 and Figure 10). The first endothermic peak, visible at a temperature range of 140–147 °C, confirms the presence of Mg stearate in the composition of the tested drugs. In this range of temperature, a slight loss of weight is observed. It means that only a small part of the drug melted. The diffraction lines derived from Mg stearate are noticeable in diffraction patterns (Figure 5).

Figure 9.

Figure 9

Open in a new tab

DSC and TG/DTG for Over-the-Counter (OTC) drugs with a sildenafil base: (a) Doppelsil® and (b) Maxigra®.

Figure 10.

Figure 10

Open in a new tab

DSC and TG/DTG for Over-the-Counter (OTC) drugs with a sildenafil base: (a) Mensil® and (b) Inventum™.

The small second endothermic peaks visible in Figure 9 and Figure 10 are at temperatures of 181–183 °C. At this temperature, no loss of mass is observed. It indicates that at this temperature, the melting process of the sildenafil base is observed. The third endothermic peak, visible in the range of temperatures 198–202 °C, indicates the melting point of lactose monohydrate, which is included. The DSC/TG results are in good agreement with the X-ray study. Together with this peak, the substantial loss mass is observed on the TG/DTG curves. The thermal parameters for this group of drugs are presented in Table 4.

Table 4.

Thermal parameters obtained from DSC/TG analysis for selected drugs containing a sildenafil base.

No. Name of Drug Weight Loss (%) Onset (°C) Offset (°C) Peak Maximum (°C) Peak Height (mW) Peak Area (J) Enthalpy (J/g)
1 DoppelSil® 57 142 150 147 2.50 0.28 68.0
174 188 183 0.71 0.02 4.22
195 207 202 2.96 0.23 55.0
2 Maxigra® 31 135 148 140 6.68 0.77 72.6
179 183 181 1.35 0.08 7.70
194 206 201 9.78 1.25 118
3 Mensil® 27 140 148 143 5.50 0.53 65.0
180 186 182 0.88 0.05 5.73
192 202 198 6.24 0.70 86.7
4 Inventum™ 24 142 150 146 4.70 0.45 73.2
180 186 182 0.88 0.04 5.73
192 202 198 6.24 0.54 86.7
Open in a new tab

3. Materials and Methods

The drugs containing sildenafil compounds were examined using the following methods: X-ray Powder Diffraction (XRPD), Thermogravimetry (TG), and Differential Scanning Calorimetry (DSC).

3.1. Materials

Twelve drugs containing sildenafil compounds were selected for the examination. Nine drugs belong to the Over-the-Counter (OTC) group of drugs. The rest of the drugs are prescription drugs: Viagra®, Ernafil®, and Sildena®. All the examined drugs are listed in Table 5, where the details containing information about the manufacturers and the amount of sildenafil compound per tablet are presented.

Table 5.

Analysed drugs containing sildenafil compounds.

No. Product Name (Manufacturer) Sildenafil Compound Content in 1 Tablet (mg) Mass (%) of Sildenafil Compound in 1 Tablet
1 Viagra® (Pfizer) 100 15.7
2 Ernafil® (Teva) 100 18.8
3 Sildena® (Hemofarm) 100 16.2
4 Valinger® (Orion Pharma) 25 16.1
5 Maxigra® (Polpharma) 25 18.5
6 Mensil® (Hasco-Lek S.A.) 25 18.8
7 DoppelSil® (Doppelherz Pharma) 25 18.1
8 Inventum™ (Aflofarm Farmacja Polska) 25 18.9
9 Maxon® (Adamed Pharma) 25 16.1
10 ActiGra® (Biofarm) 25 16.6
11 Silcontrol® (Zentiva) 25 16.1
12 PrinceX® (Accord Healthcare) 25 16.6
Open in a new tab

3.2. Methods

3.2.1. X-ray Analysis of Samples of Selected Drugs Containing Sildenafil

The tablets were crushed thoroughly in an agate mortar to obtain an excellent, homogeneous powder. Next, such prepared samples were examined using polycrystalline diffractometers: D5000 (Siemens, Munich, Germany) and PW3050 (X’Pert Philips, Malvern Panalytical, Malvern, UK), using Bragg–Brentano geometry and CuKα radiation. The time of analysis for every sample was approx. 2 h. All technical details about X-ray analysis are presented in [13,14,15]. All diffraction images are shown for a 2θ angular range of 5–30°, as the strongest diffraction lines are visible at low angles. To prepare a comparative analysis between the experimental data and the standards, we applied diffractometric data from the ICDD PDF4 database (Release 2018) [16]. For some drugs, the diffraction lines originating from excipients were identified. The numbers of the PDF cards used for diffraction line analysis are presented in Table 6.

Table 6.

List of used ICDD PDF4 (release 2018) cards.

No. Chemical Compound Chemical Formula No. PDF Card
1 sildenafil citrate C28H38N6O11S 00–052–2420
2 sildenafil base C22H30N6O4S 00–052–2006
3 lactose monohydrate C12H22O11·H2O 00–001–0333
4 magnesium stearate C36H70MgO4 00–005–0292
5 cellulose C6H10O5 00–003–0223
Open in a new tab

3.2.2. Thermal Analysis

The small amount of the tested drug (below 10 mg) was located in an aluminum crucible with a lid and heated to a temperature of 450 °C under an argon atmosphere, using a heating rate of 5 °C/min. The LabsysEvo (Setaram Inc., Cranbury, NJ, USA) apparatus was used for the thermal analysis. For every sample, the measurement was performed under the same conditions.

4. Conclusions

Studies on identifying sildenafil APIs in selected drugs were carried out using X-ray and thermal analyses. The tests were done for three prescription drugs and nine commonly available drugs in pharmacies. The X-ray analysis compared diffraction line positions (2θ angles) for the tested samples, their intensities, and the interplanar distance dhkl with data from the ICDD PDF4 database. Based on the performed measurements, it was found that the tested samples contain a sildenafil compound, as declared by the manufacturer. The difference between the values of the experimental 2θ angles and the data from a database is less than 0.2°, and the diffraction patterns are consistent with the images in the ICDD database. It indicates the use of a substance with the same structural parameters or substances with the same crystal form. Differences in the intensities of diffraction lines derived from sildenafil compounds were observed compared to data from a database. It should be highlighted that each drug is a mixture of crystalline and amorphous substances (API(s) and excipients). The intensity of the diffraction line depends not only on its amount in the examined mixture but also on the crystal structure, coexisting phases, and mass absorption coefficient of the mixture. Data presented in X-ray databases concern pure substances.

The DSC and TG curves analysis confirmed the presence of sildenafil API in the examined drugs. For all medicines, an endothermic peak (at a temperature range of 181–188 °C) was visible on the DSC curve, indicating the presence of sildenafil. Endothermic peaks originating from Mg stearate and lactose monohydrate were observed for some of the medicines. This phenomenon is in excellent agreement with the results of X-ray studies, where diffraction lines from these auxiliary substances are visible in the diffraction pattern.

Studies using a combination of two techniques, thermal analysis, and X-ray investigations, can identify active substances in drugs and distinguish genuine drugs from counterfeit, e.g., by checking the presence of the correct active substance or determining the presence of its proper polymorph. Thermal measurements allow us to determine the temperature limits below which the analysed substances can be processed without changing their physicochemical properties. The results presented in this work may be helpful as a guideline for testing the stability of various drugs and may be used to detect incompatibilities in the composition of medicines. If the X-ray study and thermal measurements provide questionable data, other methods, e.g., IR, UV-Vis, XRF, chromatographic, or microscopic, should be used [34,35,36].

Author Contributions

Conceptualisation, Visualisation, Supervision, and Administration, I.J.; Resources, I.J. and J.J.; Methodology, E.P., T.G. and J.K.; Validation, I.J., E.P. and J.J.; Investigation, I.J., E.P., T.G., J.K. and J.J.; Manuscript—Writing, I.J. and J.J. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available upon request from the corresponding authors.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compounds are available from the authors.

Funding Statement

This work was supported by the Slovak Research and Development Agency (project APVV-17-0318) and VEGA 1/0116/22.

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

References

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The data presented in this study are available upon request from the corresponding authors.

Articles from Molecules are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES